Epicutaneous immunotherapy effective against peanut allergy related symptoms among toddlers: NEJM

Medically Reviewed By : Dr. Kamal Kant Kohli

Published On 2023-05-13 03:30 GMT | Update On 2023-05-13 07:56 GMT

Epicutaneous immunotherapy for a year was effective in desensitizing kids to peanuts and lowering the peanut dosage that elicited allergic symptoms in a recent experiment conducted by Matthew Greenhawt and team, including kids aged 1 to 3 with peanut allergies. The findings of this study were published in the New England Journal of Medicine.

Children aged 1 to 3 who had a peanut allergy that had been verified by a double-blind, placebo-controlled food challenge participated in this phase 3 double-blind, randomized, multicenter, placebo-controlled study. Epicutaneous immunotherapy using a peanut patch was administered in a 2:1 ratio to patients who had an eliciting dose of 300 mg or less of peanut protein (the dose required to cause an allergic reaction) or received a placebo given daily for 12 months. The triggering dosage of peanut protein at 12 months served as the key end point for assessing the therapy response. According to the occurrence of negative side effects when using the peanut patch or a placebo, safety was evaluated.

The key findings of this study were:

1. 84.8% of the 362 patients who were randomly assigned to the experiment finished it.

2. 67.0% of kids in the intervention group and 33.5% of kids in the placebo group showed the primary efficacy end point outcome, respectively.

3. Regardless of their relation to the intervention or placebo, adverse events were seen in 100% of patients in the intervention group and in 99.2% of patients in the placebo group.

4. 8.6% of patients in the intervention group and 2.5% of patients in the placebo group experienced serious adverse events; anaphylaxis occurred in 7.8% and 3.4% of patients, respectively.

5. In the intervention group, 0.4% of patients had serious treatment-related side effects whereas none did so in the placebo group.

Reference:

Greenhawt, M., Sindher, S. B., Wang, J., O’Sullivan, M., du Toit, G., Kim, E. H., Albright, D., Anvari, S., Arends, N., Arkwright, P. D., Bégin, P., Blumchen, K., Bourrier, T., Divaret-Chauveau, A., … Burks, A. W. (2023). Phase 3 Trial of Epicutaneous Immunotherapy in Toddlers with Peanut Allergy. In New England Journal of Medicine (Vol. 388, Issue 19, pp. 1755–1766). Massachusetts Medical Society. https://doi.org/10.1056/nejmoa2212895

Article Source : New England Journal of Medicine

Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.

NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.

Jacinthlyn Sylvia

Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Epicutaneous immunotherapy effective against peanut allergy related symptoms among toddlers: NEJM

Similar News

Sex Influences Quality-of-Life Outcomes in Peanut Oral Immunotherapy: Study

Ensuring Medication Safety for Pediatric Patients in Resource-Limited Settings ,study finds

Oral Berotralstat Effective and Safe for HAE Prevention in Young Children: Study

Pregnancy Hypertension Linked to Lower Childhood IQ, Large Meta-Analysis Finds

Over Half of Indian Patients With Nasal Symptoms Have Allergic Rhinitis: Study Finds

Excessive screen time among youth may pose heart health risks: Study

Mouth Breathing Linked to Sleep-Disordered Breathing in Children, finds study

Storing breast milk for specific times of day could support babies' circadian rhythm: Study